Form 4: Metagenomi Executive Matthew Wein Reports Stock and Option Awards

Matthew Wein, a Metagenomi executive, reported the acquisition of restricted stock units and stock options in a recent SEC filing.

Summary

• On April 1, 2025, Matthew Wein, Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary of Metagenomi, Inc., reported the acquisition of 3,650 restricted stock units (RSUs) and 3,775 RSUs.
• Wein also acquired options to purchase 21,875 and 22,725 shares of common stock at an exercise price of $1.32.
• The RSUs vest over time, with 25% vesting on June 5, 2026, or March 5, 2026, respectively, and the remainder vesting in equal quarterly installments thereafter, contingent upon continued service.
• The stock options vest with 25% becoming exercisable on April 1, 2026, and the remainder vesting in 36 equal monthly installments, also subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity-based compensation is generally viewed favorably as it aligns management's interests with those of shareholders. However, the impact is not significant enough to warrant a higher score.

Positives

• The granting of RSUs and stock options to a key executive like Matthew Wein can be seen as an incentive to align his interests with the long-term success of Metagenomi.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service with the Issuer.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholder value.

Stakeholder Impact

• Shareholders may view the granting of RSUs and stock options positively as it incentivizes management to improve company performance.

Key Dates

Keywords

Metagenomi, Matthew Wein, stock options, restricted stock units, RSUs, Form 4, insider trading